Policy Reports

2020

  • Marcus H, Roevers M, Martin J, McCulloch P. IDEAL-D framework for device innovation: the preclinical stage. 2020 Submitted.
  • Bruns M, Manojkumar A, Hartwell M, Roberts W, White B, Young J, Arthur W, Ottwell R, Martin J, Wright DN, Vassar M. Evaluation of spin in the abstracts of systematic reviews and meta-analyses covering postoperative nausea and vomiting. 2020 Submitted.
  • Bradley S, DeVito N, Lloyd K, Richards G, Rombey T, Wayand C, Gill P, on behalf of the Declaration for reducing bias and improving transparency in medical research. Declaration for Reducing bias and improving transparency in medical research: a critical overview of the problems, progress so far and suggested next steps. 2020 Submitted.
  • Clarke M, Ciliska D, Martin J, Ban JW, Brunnhuber K, Robinson K, Juhl C, Henriksen M, Tugwell P, Blane C, Christensen R, Andreasen J, Nasser M, Norgaard B, Draborg E, Lund H. Using an evidence-based research approach to place your results into context after the study is performed to ensure usefulness of the conclusion. 2020 Submitted.
  • Hachinski V, Arzanpour R, for the Dementia Prevention Initiative. Do we need a more comprehensive approach? 2020 Submitted.
  • Robinson KA, Brunnhuber K, Ciliska D, Juhl CB, Christensen R, Lund H, on behalf of the Evidence-Based Research Network. What is evidence-based research and why is it important? J Clin Epi 2020. https://doi.org/10.1016/j.jclinepi.2020/07.020
  • Lund H, Juhl CB, Norgaard B, Draborg E, Henriksen M, Andreasen J, Christensen R, Nasser M, Ciliska D, Clarke M, Tugwell P, Martin J, Blaine C, Brunnhuber K, Robinson KA, on behalf of the Evidence-Based Research Network. Using an evidence-based research approach before a new study is conducted to ensure value. J Clin Epi 2020 doi: https://doi.org/10.1016/j.jclinepi.2020.07.019
  • Lund H, Juhl C, Borgaard B, Draborg E, Henriksen M, Andreasen J, Christensen R, Nasser M, Ciliska D, Tugwell P, Clarke M, Blaine C, Martin J, Ban JW, Brunnhuber K, Robinson K. Using an evidence-based research approach to place your results into context after the study is performed to ensure usefulness of the conclusion. J Clin Epi 2020 https://doi.org/10.1016/j.jclinepi.2020.07.021
  • Qureshi R, Sutton D, Martin J. Approaching evidence reversal and medical reversal – when to say ‘enough is enough’. 2020 Submitted.
  • Odland ML, Nepogodiev D, Morton D, Martin J, Bekele A, Davis J, Weiser T. Defining a basket of surgical procedures to assess surgical care: an international Delphi study. 2020 Ann Surg In Press.

2019

  • Stafinski T, Deber R, Rhainds M, Martin J, Noseworthy T, Bryan S, Menon D. Decision-making on new non-drug health technologies (NDTs) by hospitals and health authorities in Canada. Healthcare Policy 2019;15(1):82-94. doi:10.12927/hcpol.2019.25936
  • Stafinski T, Deber R, Rhainds M, Martin J, Noseworthy T, Bryan S, Menon D. The introduction of new non-drug health technologies (NDTs) into Canadian healthcare institutions: Opportunities and challenges. Healthcare Policy 2019;15(1):95-106. doi:10.12927/hcpol.2019.25935
  • Pichler F, Oortwijn W, Ruether A, Trowman R, Cheng Y, Marti S, Martin J, Pichon Riviere A, Scott A, Ziao Y; on behalf of the HTAi Scientific Development and Capacity Building Committee. Defining capacity building in the context of HTA: a proposal by the HTAi Scientific Development and Capacity Building Committee. Int J Tech Assess Health Care 2019;35(5):362-366. doi.org/10.1017/S0266462319000631

2018

  • Martin J. Complementary roles of global, national, and local health technology assessment. Int J Hosp Based Health Technol Assess 2018;1:1-2. http://dx.doi.org/10.21965/IJHBHTA.2018.E
  • Sutton D, Qureshi R, Martin J. Evidence reversal-when new evidence contradicts current claims: A systematic overview review. J Clin Epidemiol. 2018;94:76-84. https://doi.org/10.1016/j.jclinepi.2017.10.004
  • Recommendation Framework for Ontario Drug Decisions: Advice for the Ontario MOHLTC Committee to Evaluate Drugs, 2018.
  • Deliberative Framework for Ontario Public Drug Decisions: Recommendations for the Ontario MOHLTC Committee to Evaluate Drugs, 2018.

2017

  • Martin JCheng D, Stranges S. Population health intervention research: myths and misconceptions. Int J Public Health. 2017;62(8):845-847. https://doi.org/10.1007/s00038-017-0992-3
  • Choosing Wisely Canada, Critical Care Campaign Task Force: Critical Care: Five things clinicians and Patients should question (Practice Guidelines) 2017 March 22. Available from http:// choosingwiselycanada. org/recommendations/ critical-care/

2016

  • Martin J, Polisena J, Dendukuri N, Rhainds M, Sampietro-Colom L. Local health technology assessment in Canada: Current state and next steps. Int J Technol Assess Health Care. 2016;32(3):175-80. PMID: 27491840. doi: 10.1017/S0266462316000210

2015

  • Polisena J, Lavis J, Graham I, Harstall C, Juzwishin D, Veysey-McLean P, Martin J. Supporting the use of health technology assessments in decision makers. Healthcare Policy. 2015 May;10(4):10-15. PMID: 26142355. doi:10.12927/hcpol.2015.24208
  • Martin J, Invited Contributor to: “Unleashing Innovation: Excellent Healthcare for Canada. Report of the Advisory Panel on Healthcare Innovation”, submitted to the Honourable Rona Ambrose, Minister of Health, Government of Canada, 2015. MEDICI's Role: To contribute to the chapter on healthcare innovation.
  • Martin JCheng D. The real cost of care: focus on value for money, rather than price-tags. Can J Anesth. 2015 Oct;62(10):1034-41. PMID: 26275788. https://doi.org/10.1007/s12630-015-0444-6

2014

  • HTA Exchange. Ethical, Legal, Social & Implementation Issues in Health Technology Assessment. Report of the HTA Exchange National Retreat to the Canadian Agency for Drugs and Technologies in Health, Nov 2014.
    MEDICI's Role: To Chair the national retreat, and to oversee the engagement with HTA methodologists and decision-makers, and contribute to writing and circulating the report for feedback.
  • Clarke JTR, Coyle D, Evans G, Martin J, Winquist E. Toward a functional definition of ‘rare disease’ for regulatory agencies and funding agencies. Value in Health. 2014;17(8):757-61. PMID: 25498770.  https://doi.org/10.1016/j.jval.2014.08.2672

2013

  • Tanios N, Wagner M, Tony M, Baltussen R, van Til J, Rindress D, Kind P, Goetghebeur MM; International Task Force on Decision Criteria (Ferraz MB, Carrasqueiro S, Chinitz D, Chitama D, Clifford T, Cumming J, Diaby V, Flamion B, Gerber-Grote A, Goeree R, Guindo A, Harstall C, Jacobs P, Jehu-Appiah C, Kletchko S, Lettieri E, Longworth L, Martin J, McDonald K, Miot J, Niessen L, Paolucci F, Peacock S, Poulin P, Raisch DW, Rajasekaran S, Ryan F, Siebert U, Tringali M, Waldau S, Wong P). Which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision makers. Int J Technol Assess Health Care. 2013;29(4):456-65. PMID: 24290340. https://doi.org/10.1017/S0266462313000573
  • Coyle D, Bell CM, Clarke JTR, Evans G, Gadhok A, Martin J, Sabharwal M, Winquist E. Application of operations research to funding decisions for treatments with rare disease. Operations Res Health Care Policy. 2013;190:281-294. https://doi.org/10.1007/978-1-4614-6507-2_13
  • Martin JCheng D. Role of the anesthesiologist in the wider governance of healthcare and health economics. Can J Anesth. 2013;60(9):918-28. PMID: 23820969. https://doi.org/10.1007/s12630-013-9994-7

2012

  • Government of Canada White Paper. Health Technology Assessment, Health Technology Management and Decision-Making in Canada: Combining Evidence, Economics, and Contextualized Social-Legal-Ethical-Implementation Issues to Improve Healthcare in Care, Jan 2012. White paper invited by Health Canada to explore Know4Go as an innovative framework to link the evidence, economics, ethics (and other essential ‘sleeper’ aspects that influence decision-making), in order to make explicit the multidimensional opportunity cost “tradeoffs” when assessing multiple technologies at various levels of decision-informing (national planning, government and regional decision-making and implementation). The potential for using the framework to visualize the dependent links and tradeoffs between technology uptake and disinvestment was proposed from a variety of perspectives as a basis to increase national coordination of health technology assessment and management, while respecting the need to maintain independence and contextualization at the provincial level. Linking planning, assessment, implementation, with real-world outcomes feedback into the framework was emphasized.
  • Winquist E, Coyle D, Evans G, Clark J, Chan W, Sabharwal M, Martin J. Policy Framework for Drugs for Rare Diseases, Ontario Framework for Drugs for Rare Diseases (DRDs), co-developer of policy for drugs for rare diseases. This policy framework was developed to guide Ontario policy decisions related to drugs for rare and ultra-orphan diseases. In 2011-2013, given the progression toward a national approach to rare disease formulary decisions in Canada, this policy framework was used to inform the design of the national framework for rare disease drug funding. MEDICI's Role: Dr. Janet Martin co-developed the original framework by contributing to developing the policy question, performing underlying research, synthesizing evidence, and trialing the framework iteratively to real-world requests for drugs for rare diseases at the Ontario Ministry of Health, oversaw the process and manuscript as senior author.
  • Jones DJ, Barkun AN, Lu Y, Enns R, Sinclair P, Martel M, Gralnek I, Bardou M, Kuipers EJ, Sung J; International Consensus Upper Gastrointestinal Bleeding Conference Group (Agreus L, Armstrong D, Calvet X, Chiba N, Cipolletta L, Cohen H, Ericsson LG, Hunt R, Jensen D, Kaminishi M, Kanwal F, Laine L, Lanas A, Lau J, Leontiadis G, Lundell L, Malfertheiner P, Marshall J, Martin J, Metz D, Moayyedi P, Quenot JP, Rauws E, Romagnuolo J, Rostom A, Spiegel B, Tse F, Van Leerdam M, Van Rensburg C). Conflicts of interest ethics: silencing expertise in the development of international clinical practice guidelines. Ann Intern Med. 2012;156(11):809-16, W-283. PMID: 22665816. https://doi.org/10.7326/0003-4819-156-11-201206050-00008
  • Winquist E, Bell CM, Clarke JT, Evans G, Martin J, Sabharwal M, Gadhok A, Stevenson H, Coyle D. An evaluation framework for funding drugs for rare diseases. Value Health. 2012;15(6):982-6. PMID: 22999151. https://doi.org/10.1016/j.jval.2012.06.009
  • Hall R, Chisholm R, Cheng D, Murphy M, Campbell D. Drug shortages in anesthesia and perioperative medicine: Canada needs a better supply system. Can J Anaesth. 2012;59(7):629-635. https://doi.org/10.1007/s12630-012-9709-5

2011

  • Cheng DMartin J. Evidence-based practice and health technology assessment: a call for anesthesiologists to engage in knowledge translation. Can J Anesth. 2011;58(4):354-63. PMID: 21264556.  https://doi.org/10.1007/s12630-011-9463-0

2010

  • Hall R, Beattie S, Cheng D, Choi P, Denault AY, Mazer D, Mutch WA, Turgeon AF, Yang H. Can We Develop A Canadian Perioperative Anesthesiology Clinical Trials Group? Can J Anaesth. 2010 Dec;57(12):1051-1057. DOI: 10.1007/s12630-010-9385-2 

2010-Present

  • Approximately 30 policy advice reports (confidential) to the Committee to Evaluate Drugs and the Executive Officer of the Minister of Health, Ontario Ministry of Health and Long Term Care.